- Home
- DGHI vs ARMP Comparison
DGHI vs ARMP Comparison
Compare DGHI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- ARMP
- Stock Information
- Founded
- DGHI 2017
- ARMP N/A
- Country
- DGHI United States
- ARMP United States
- Employees
- DGHI N/A
- ARMP N/A
- Industry
- DGHI Finance: Consumer Services
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGHI Finance
- ARMP Health Care
- Exchange
- DGHI Nasdaq
- ARMP Nasdaq
- Market Cap
- DGHI 90.1M
- ARMP 80.0M
- IPO Year
- DGHI N/A
- ARMP N/A
- Fundamental
- Price
- DGHI $1.95
- ARMP $2.11
- Analyst Decision
- DGHI Strong Buy
- ARMP Strong Buy
- Analyst Count
- DGHI 1
- ARMP 1
- Target Price
- DGHI $2.50
- ARMP $7.00
- AVG Volume (30 Days)
- DGHI 975.9K
- ARMP 8.2K
- Earning Date
- DGHI 04-02-2025
- ARMP 03-20-2025
- Dividend Yield
- DGHI N/A
- ARMP N/A
- EPS Growth
- DGHI N/A
- ARMP N/A
- EPS
- DGHI N/A
- ARMP N/A
- Revenue
- DGHI $42,146,057.00
- ARMP $5,467,000.00
- Revenue This Year
- DGHI N/A
- ARMP $23.87
- Revenue Next Year
- DGHI N/A
- ARMP N/A
- P/E Ratio
- DGHI N/A
- ARMP N/A
- Revenue Growth
- DGHI 100.56
- ARMP 34.92
- 52 Week Low
- DGHI $0.84
- ARMP $1.80
- 52 Week High
- DGHI $3.77
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- DGHI 37.60
- ARMP 56.44
- Support Level
- DGHI $2.81
- ARMP $1.85
- Resistance Level
- DGHI $3.48
- ARMP $2.08
- Average True Range (ATR)
- DGHI 0.35
- ARMP 0.12
- MACD
- DGHI -0.15
- ARMP 0.00
- Stochastic Oscillator
- DGHI 4.12
- ARMP 56.67
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.